Jeff Evanson - Mar 31, 2022 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role
Chief Commercial Officer
Signature
/s/ Lawrence Kenyon, Attorney-in-Fact
Stock symbol
OTLK
Transactions as of
Mar 31, 2022
Transactions value $
$0
Form type
4
Date filed
4/4/2022, 06:47 PM
Previous filing
Dec 23, 2021
Next filing
Jan 19, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLK Stock Option (Right to Buy) Award $0 +100K $0.00 100K Mar 31, 2022 Common Stock 100K $1.44 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares that vested under a performance-based stock option grant based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based vesting conditions of the option, such shares were not reportable under Section 16 until vesting was determined, which occurred on March 31, 2022. The vested shares represents the first of three possible vesting events of the total number of shares subject to the option. The remaining shares subject to the option will vest only upon the satisfaction of additional performance vesting criteria.
F2 Fully vested and immediately exercisable.